This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Apfel, C. M.
Right arrow Articles by Keck, W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Apfel, C. M.
Right arrow Articles by Keck, W.

 Previous Article  |  Next Article 

Antimicrobial Agents and Chemotherapy, April 2001, p. 1058-1064, Vol. 45, No. 4
0066-4804/01/$04.00+0   DOI: 10.1128/AAC.45.4.1058-1064.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.

Peptide Deformylase as an Antibacterial Drug Target: Target Validation and Resistance Development

Christian M. Apfel,* Hans Locher,dagger Stefan Evers, Béla Takács, Christian Hubschwerlen,dagger Wolfgang Pirson, Malcolm G. P. Page, and Wolfgang Keckdagger

Pharma Research Basel, F. Hoffmann-La Roche Ltd., CH-4070 Basel, Switzerland

Received 10 August 2000/Returned for modification 5 October 2000/Accepted 20 December 2000

New inhibitors of peptide deformylase (PDF) which are very potent against the isolated enzyme and show a certain degree of antibacterial activity have recently been synthesized by our group. Several lines of experimental evidence indicate that these inhibitors indeed interfere with the target enzyme in the bacterial cell. (i) The inhibition of Escherichia coli growth could be counteracted by overexpression of PDF from different organisms, including E. coli, Streptococcus pneumoniae, and Haemophilus influenzae. Conversely, reduced expression of PDF in S. pneumoniae resulted in an increased susceptibility to the inhibitors. (ii) Proteome analysis on two-dimensional gels revealed a shift for many proteins towards lower pI in the presence of PDF inhibitors, as would be expected if the proteins still carry their N-formyl-Met terminus. (iii) PDF inhibitors show no antimicrobial activity against E. coli under conditions that make growth independent of formylation and deformylation. The antibacterial activity in E. coli was characterized as bacteriostatic. Furthermore, the development of resistance in E. coli was observed to occur with high frequency (10-7). Resistant mutants show a reduced growth rate, and DNA sequence analysis revealed mutations in their formyl transferase gene. Taking all these aspects into account, we conclude that PDF may not be an optimal target for broad-spectrum antibacterial agents.

* Corresponding author. Mailing address: F. Hoffmann-La Roche Ltd., PRBM-H, Bldg. 69/11A, CH-4070 Basel, Switzerland. Phone: 41 61 688 5878. Fax: 41 61 688 2377. E-mail: christian.apfel{at}roche.com.

dagger Present address: Morphochem AG, Basel, Switzerland.

Antimicrobial Agents and Chemotherapy, April 2001, p. 1058-1064, Vol. 45, No. 4
0066-4804/01/$04.00+0   DOI: 10.1128/AAC.45.4.1058-1064.2001
Copyright © 2001, American Society for Microbiology. All rights reserved.


This article has been cited by other articles:

  • Duroc, Y., Giglione, C., Meinnel, T. (2009). Mutations in Three Distinct Loci Cause Resistance to Peptide Deformylase Inhibitors in Bacillus subtilis. Antimicrob. Agents Chemother. 53: 1673-1678 [Abstract] [Full Text]  
  • Biswas, I., Jha, J. K., Fromm, N. (2008). Shuttle expression plasmids for genetic studies in Streptococcus mutans. Microbiology 154: 2275-2282 [Abstract] [Full Text]  
  • Dean, C. R., Narayan, S., Richards, J., Daigle, D. M., Esterow, S., Leeds, J. A., Kamp, H., Puyang, X., Wiedmann, B., Mueller, D., Voshol, H., van Oostrum, J., Wall, D., Koehn, J., Dzink-Fox, J., Ryder, N. S. (2007). Reduced Susceptibility of Haemophilus influenzae to the Peptide Deformylase Inhibitor LBM415 Can Result from Target Protein Overexpression Due to Amplified Chromosomal def Gene Copy Number. Antimicrob. Agents Chemother. 51: 1004-1010 [Abstract] [Full Text]  
  • Liebscher, M., Jahreis, G., Lucke, C., Grabley, S., Raina, S., Schiene-Fischer, C. (2007). Fatty Acyl Benzamido Antibacterials Based on Inhibition of DnaK-catalyzed Protein Folding. J. Biol. Chem. 282: 4437-4446 [Abstract] [Full Text]  
  • Teo, J. W. P., Thayalan, P., Beer, D., Yap, A. S. L., Nanjundappa, M., Ngew, X., Duraiswamy, J., Liung, S., Dartois, V., Schreiber, M., Hasan, S., Cynamon, M., Ryder, N. S., Yang, X., Weidmann, B., Bracken, K., Dick, T., Mukherjee, K. (2006). Peptide Deformylase Inhibitors as Potent Antimycobacterial Agents. Antimicrob. Agents Chemother. 50: 3665-3673 [Abstract] [Full Text]  
  • Nilsson, A. I., Zorzet, A., Kanth, A., Dahlstrom, S., Berg, O. G., Andersson, D. I. (2006). Reducing the fitness cost of antibiotic resistance by amplification of initiator tRNA genes. Proc. Natl. Acad. Sci. USA 103: 6976-6981 [Abstract] [Full Text]  
  • Wang, W., White, R., Yuan, Z. (2006). Proteomic Study of Peptide Deformylase Inhibition in Streptococcus pneumoniae and Staphylococcus aureus.. Antimicrob. Agents Chemother. 50: 1656-1663 [Abstract] [Full Text]  
  • Saxena, R., Chakraborti, P. K. (2005). Identification of Regions Involved in Enzymatic Stability of Peptide Deformylase of Mycobacterium tuberculosis. J. Bacteriol. 187: 8216-8220 [Abstract] [Full Text]  
  • Fonseca-Aten, M., Salvatore, C. M., Mejias, A., Rios, A. M., Chavez-Bueno, S., Katz, K., Gomez, A. M., McCracken, G. H. Jr, Hardy, R. D. (2005). Evaluation of LBM415 (NVP PDF-713), a Novel Peptide Deformylase Inhibitor, for Treatment of Experimental Mycoplasma pneumoniae Pneumonia. Antimicrob. Agents Chemother. 49: 4128-4136 [Abstract] [Full Text]  
  • Dean, C. R., Narayan, S., Daigle, D. M., Dzink-Fox, J. L., Puyang, X., Bracken, K. R., Dean, K. E., Weidmann, B., Yuan, Z., Jain, R., Ryder, N. S. (2005). Role of the AcrAB-TolC Efflux Pump in Determining Susceptibility of Haemophilus influenzae to the Novel Peptide Deformylase Inhibitor LBM415. Antimicrob. Agents Chemother. 49: 3129-3135 [Abstract] [Full Text]  
  • Waites, K. B., Reddy, N. B., Crabb, D. M., Duffy, L. B. (2005). Comparative In Vitro Activities of Investigational Peptide Deformylase Inhibitor NVP LBM-415 and Other Agents against Human Mycoplasmas and Ureaplasmas. Antimicrob. Agents Chemother. 49: 2541-2542 [Abstract] [Full Text]  
  • Fritsche, T. R., Sader, H. S., Cleeland, R., Jones, R. N. (2005). Comparative Antimicrobial Characterization of LBM415 (NVP PDF-713), a New Peptide Deformylase Inhibitor of Clinical Importance. Antimicrob. Agents Chemother. 49: 1468-1476 [Abstract] [Full Text]  
  • Bell, J. M., Turnidge, J. D., Inoue, M., Kohno, S., Hirakata, Y., Ono, Y., Jones, R. N. (2005). Activity of a peptide deformylase inhibitor LBM415 (NVP PDF-713) tested against recent clinical isolates from Japan. J Antimicrob Chemother 55: 276-278 [Full Text]  
  • Hutter, B., Fischer, C., Jacobi, A., Schaab, C., Loferer, H. (2004). Panel of Bacillus subtilis Reporter Strains Indicative of Various Modes of Action. Antimicrob. Agents Chemother. 48: 2588-2594 [Abstract] [Full Text]  
  • Jones, R. N., Moet, G. J., Sader, H. S., Fritsche, T. R. (2004). Potential utility of a peptide deformylase inhibitor (NVP PDF-713) against oxazolidinone-resistant or streptogramin-resistant Gram-positive organism isolates. J Antimicrob Chemother 53: 804-807 [Abstract] [Full Text]  
  • Cynamon, M. H., Alvirez-Freites, E., Yeo, A. E. T. (2004). BB-3497, a peptide deformylase inhibitor, is active against Mycobacterium tuberculosis. J Antimicrob Chemother 53: 403-405 [Full Text]  
  • Chan, P. F., O'Dwyer, K. M., Palmer, L. M., Ambrad, J. D., Ingraham, K. A., So, C., Lonetto, M. A., Biswas, S., Rosenberg, M., Holmes, D. J., Zalacain, M. (2003). Characterization of a Novel Fucose-Regulated Promoter (PfcsK) Suitable for Gene Essentiality and Antibacterial Mode-of-Action Studies in Streptococcus pneumoniae. J. Bacteriol. 185: 2051-2058 [Abstract] [Full Text]  
  • Jones, R. N., Rhomberg, P. R. (2003). Comparative spectrum and activity of NVP-PDF386 (VRC4887), a new peptide deformylase inhibitor. J Antimicrob Chemother 51: 157-161 [Abstract] [Full Text]  
  • Hackbarth, C. J., Chen, D. Z., Lewis, J. G., Clark, K., Mangold, J. B., Cramer, J. A., Margolis, P. S., Wang, W., Koehn, J., Wu, C., Lopez, S., Withers, G. III, Gu, H., Dunn, E., Kulathila, R., Pan, S.-H., Porter, W. L., Jacobs, J., Trias, J., Patel, D. V., Weidmann, B., White, R. J., Yuan, Z. (2002). N-Alkyl Urea Hydroxamic Acids as a New Class of Peptide Deformylase Inhibitors with Antibacterial Activity. Antimicrob. Agents Chemother. 46: 2752-2764 [Abstract] [Full Text]  
  • Apfel, C. M., Evers, S., Hubschwerlen, C., Pirson, W., Page, M. G. P., Keck, W. (2001). Peptide Deformylase as an Antibacterial Drug Target: Assays for Detection of Its Inhibition in Escherichia coli Cell Homogenates and Intact Cells. Antimicrob. Agents Chemother. 45: 1053-1057 [Abstract] [Full Text]  


Copyright © 2009 by the American Society for Microbiology.   For an alternate route to Journals.ASM.org, visit: http://intl-journals.asm.org | More Info»